Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12710330 | 0.95 | MEN1 (0.46) | MEN1KMT2AGPBAR1RAB9ATSHR | |
| SCHEMBL439358 | 0.84 | GPBAR1 (0.41) | MEN1KMT2AGPBAR1RAB9ATSHR | |
| SCHEMBL1547672 | 0.84 | GPBAR1 (0.43) | MEN1KMT2AGPBAR1RAB9ATSHR | |
| SCHEMBL12710361 | 0.83 | GPBAR1 (0.40) | MEN1KMT2AGPBAR1RAB9ATSHR | |
| SCHEMBL12710329 | 0.83 | GPBAR1 (0.40) | MEN1KMT2AGPBAR1RAB9ATSHR | |
| SCHEMBL12710332 | 0.82 | SLC6A2 (0.45) | MEN1KMT2AGPBAR1RAB9ATSHR | |
| SCHEMBL16335828 | 0.82 | GPBAR1 (0.40) | MEN1KMT2AGPBAR1RAB9ATSHR | |
| SCHEMBL440745 | 0.82 | GPBAR1 (0.47) | MEN1KMT2AGPBAR1RAB9ATSHR | |
| SCHEMBL16335775 | 0.81 | TSHR (0.40) | MEN1KMT2AGPBAR1RAB9ATSHR | |
| SCHEMBL16335564 | 0.81 | TSHR (0.39) | MEN1KMT2AGPBAR1RAB9ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082036-A1 | Active Compound Combinations Comprising Arylamidines and N-Cycloalkylamides | BAYER CROPSCIENCE AG (DE) | 2011-04-07 | — | — | US | disclosed |
| US-20110082036-A1 | Active Compound Combinations Comprising Arylamidines and N-Cycloalkylamides | BAYER CROPSCIENCE AG (DE) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082036-A1 | Active Compound Combinations Comprising Arylamidines and N-Cycloalkylamides | NAT1, NACA, AADAC | MEN1 3749/4885KMT2A 1258/4885GPBAR1 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.